Endothelium-derived nitric oxide and vascular physiology and pathology - PubMed (original) (raw)
Review
Endothelium-derived nitric oxide and vascular physiology and pathology
J F Arnal et al. Cell Mol Life Sci. 1999 Jul.
Abstract
In 1980, Furchgott and Zawadzki demonstrated that the relaxation of vascular smooth muscle cells in response to acetylcholine is dependent on the anatomical integrity of the endothelium. Endothelium-derived relaxing factor was identified 7 years later as the free radical gas nitric oxide (NO). In endothelium, the amino acid L-arginine is converted to L-citrulline and NO by one of the three NO synthases, the endothelial isoform (eNOS). Shear stress and cell proliferation appear to be, quantitatively, the two major regulatory factors of eNOS gene expression. However, eNOS seems to be mainly regulated by modulation of its activity. Stimulation of specific receptors to various agonists (e.g., bradykinin, serotonin, adenosine, ADP/ATP, histamine, thrombin) increases eNOS enzymatic activity at least in part through an increase in intracellular free Ca2+. However, the mechanical stimulus shear stress appears again to be the major stimulus of eNOS activity, although the precise mechanisms activating the enzyme remain to be elucidated. Phosphorylation and subcellular translocation (from plasmalemmal caveolae to the cytoskeleton or cytosol) are probably involved in these regulations. Although eNOS plays a major vasodilatory role in the control of vasomotion, it has not so far been demonstrated that a defect in endothelial NO production could be responsible for high blood pressure in humans. In contrast, a defect in endothelium-dependent vasodilation is known to be promoted by several risk factors (e.g., smoking, diabetes, hypercholesterolemia) and is also the consequence of atheroma (fatty streak infiltration of the neointima). Several mechanisms probably contribute to this decrease in NO bioavailability. Finally, a defect in NO generation contributes to the pathophysiology of pulmonary hypertension. Elucidation of the mechanisms of eNOS enzyme activity and NO bioavailability will contribute to our understanding the physiology of vasomotion and the pathophysiology of endothelial dysfunction, and could provide insights for new therapies, particularly in hypertension and atherosclerosis.
Similar articles
- Targeting and translocation of endothelial nitric oxide synthase.
Michel T. Michel T. Braz J Med Biol Res. 1999 Nov;32(11):1361-6. doi: 10.1590/s0100-879x1999001100006. Braz J Med Biol Res. 1999. PMID: 10559837 Review. - Cellular signaling and NO production.
Michel T, Vanhoutte PM. Michel T, et al. Pflugers Arch. 2010 May;459(6):807-16. doi: 10.1007/s00424-009-0765-9. Epub 2010 Jan 16. Pflugers Arch. 2010. PMID: 20082095 Free PMC article. Review. - Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis.
Sonveaux P, Martinive P, DeWever J, Batova Z, Daneau G, Pelat M, Ghisdal P, Grégoire V, Dessy C, Balligand JL, Feron O. Sonveaux P, et al. Circ Res. 2004 Jul 23;95(2):154-61. doi: 10.1161/01.RES.0000136344.27825.72. Epub 2004 Jun 17. Circ Res. 2004. PMID: 15205364 - Signal transduction of eNOS activation.
Fleming I, Busse R. Fleming I, et al. Cardiovasc Res. 1999 Aug 15;43(3):532-41. doi: 10.1016/s0008-6363(99)00094-2. Cardiovasc Res. 1999. PMID: 10690325 Review. - Heat shock protein 90 and tyrosine kinase regulate eNOS NO* generation but not NO* bioactivity.
Ou J, Fontana JT, Ou Z, Jones DW, Ackerman AW, Oldham KT, Yu J, Sessa WC, Pritchard KA Jr. Ou J, et al. Am J Physiol Heart Circ Physiol. 2004 Feb;286(2):H561-9. doi: 10.1152/ajpheart.00736.2003. Epub 2003 Oct 9. Am J Physiol Heart Circ Physiol. 2004. PMID: 14551044
Cited by
- How Nitric Oxide Hindered the Search for Hemoglobin-Based Oxygen Carriers as Human Blood Substitutes.
Samaja M, Malavalli A, Vandegriff KD. Samaja M, et al. Int J Mol Sci. 2023 Oct 4;24(19):14902. doi: 10.3390/ijms241914902. Int J Mol Sci. 2023. PMID: 37834350 Free PMC article. Review. - Latanoprostene Bunod 0.024% in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Meta-Analysis.
Lo TC, Chen YY, Hung MC, Chou P. Lo TC, et al. J Clin Med. 2022 Jul 26;11(15):4325. doi: 10.3390/jcm11154325. J Clin Med. 2022. PMID: 35893417 Free PMC article. Review. - Oral versus intravenous sildenafil for pulmonary hypertension in neonates: a randomized trial.
Chetan C, Suryawanshi P, Patnaik S, Soni NB, Rath C, Pareek P, Gupta B, Garegrat R, Verma A, Singh Y. Chetan C, et al. BMC Pediatr. 2022 May 27;22(1):311. doi: 10.1186/s12887-022-03366-3. BMC Pediatr. 2022. PMID: 35624452 Free PMC article. Clinical Trial. - The Inflammatory Cytokine IL-3 Hampers Cardioprotection Mediated by Endothelial Cell-Derived Extracellular Vesicles Possibly via Their Protein Cargo.
Penna C, Femminò S, Tapparo M, Lopatina T, Fladmark KE, Ravera F, Comità S, Alloatti G, Giusti I, Dolo V, Camussi G, Pagliaro P, Brizzi MF. Penna C, et al. Cells. 2020 Dec 23;10(1):13. doi: 10.3390/cells10010013. Cells. 2020. PMID: 33374685 Free PMC article. - The inflammasome NLRP3 plays a dual role on mouse corpora cavernosa relaxation.
Fais RS, Rodrigues FL, Pereira CA, Mendes AC, Mestriner F, Tostes RC, Carneiro FS. Fais RS, et al. Sci Rep. 2019 Nov 7;9(1):16224. doi: 10.1038/s41598-019-52831-0. Sci Rep. 2019. PMID: 31700106 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous